Moraxella catarrhalis is a type of bacteria that commonly lives in the nose and throat, particularly in young children. While it often causes no symptoms at all, it can lead to ear infections, sinus infections, and respiratory illnesses, especially in children under five and adults with chronic lung disease. It ranks among the top three bacterial causes of ear infections in kids, alongside Streptococcus pneumoniae and Haemophilus influenzae.
What Kind of Bacterium Is It?
Under a microscope, Moraxella catarrhalis appears as pairs of round cells with flattened sides pressed together, a shape microbiologists call a diplococcus. It is gram-negative, meaning it has a thin cell wall surrounded by an outer membrane. This detail matters because it affects which antibiotics work against it and how the immune system recognizes it.
The bacterium has gone through several name changes over the years. It was previously classified as Neisseria catarrhalis and later Branhamella catarrhalis before being reassigned to the genus Moraxella in 1984. For decades, doctors considered it a harmless inhabitant of the upper airway. That view has shifted substantially as research confirmed its role in causing real disease.
Where It Lives and How It Spreads
Moraxella catarrhalis colonizes the nasopharynx, the space behind the nose that connects to the throat. In studies of healthy children, about 12% carried the bacterium at any given time. Colonization rates are highest in infants and toddlers and tend to decline with age as the immune system matures. The bacteria spread through respiratory droplets and direct contact, much like the common cold.
Carrying the bacterium does not automatically mean infection. Many children harbor it without any symptoms. Problems arise when the bacteria migrate from the nasopharynx into normally sterile spaces like the middle ear, sinuses, or lower airways, often following a viral respiratory infection that disrupts the body’s usual defenses.
Infections in Children
In children, Moraxella catarrhalis most commonly causes acute otitis media (middle ear infections), sinusitis, and bronchitis. It can also cause tracheitis, pneumonia, and less frequently, eye infections or bloodstream infections.
Ear infections get the most attention. In a large study tracking nearly 13,000 episodes of acute otitis media, Moraxella catarrhalis was isolated in about 5% of culture-positive cases. That puts it well behind Haemophilus influenzae (48%) and Streptococcus pneumoniae (43%), but it still accounts for a meaningful number of infections. Notably, about two-thirds of the time it was found alongside another pathogen rather than acting alone, suggesting it often teams up with other bacteria during ear infections.
Infections in Adults
In adults, Moraxella catarrhalis primarily targets people who already have compromised airways. It causes laryngitis, bronchitis, and pneumonia, with the highest risk in people living with chronic obstructive pulmonary disease (COPD), the elderly, and those with weakened immune systems.
For people with COPD, this bacterium is a significant trigger of flare-ups. It causes roughly 10% of all COPD exacerbations, which translates to an estimated 2 to 4 million episodes per year. These flare-ups typically happen when a person picks up a new strain of the bacterium rather than from a strain already living in their airways. Research has shown that during exacerbations, the body mounts a stronger immune response in the bloodstream compared to times when the bacteria colonize quietly, suggesting the infection reaches deeper into the lungs during a flare-up. The bacterium is typically carried for about a month during an exacerbation, slightly shorter than the 40-day average seen with symptom-free colonization.
How It Causes Disease
Moraxella catarrhalis uses several strategies to establish infection. It produces surface proteins called adhesins that help it latch onto the cells lining the respiratory tract. Once attached, it can evade the complement system, a branch of the immune system designed to kill bacteria on contact. This allows it to survive on mucous membranes that would normally clear it.
The bacterium also breaks down a natural protective protein in the airways, which increases tissue damage and creates more attachment points for additional bacteria. It can form biofilms, structured communities of bacteria encased in a protective matrix that are harder for both the immune system and antibiotics to penetrate. These biofilms may help explain why some infections persist or recur despite treatment.
Why Standard Penicillin Doesn’t Work
One of the most clinically important facts about Moraxella catarrhalis is its near-universal resistance to basic penicillin-type antibiotics. About 96% of clinical isolates now produce enzymes called beta-lactamases (specifically BRO-1 and BRO-2) that break down penicillin and amoxicillin before they can do their job.
This means that plain amoxicillin, which is otherwise a go-to antibiotic for ear and sinus infections, often won’t work when Moraxella catarrhalis is the culprit. Instead, doctors typically prescribe antibiotics that can resist these enzymes. Amoxicillin combined with a beta-lactamase inhibitor is one common option. Certain cephalosporins (a related class of antibiotics) are also effective, as are macrolide antibiotics like azithromycin and clarithromycin. The specific choice depends on the type and location of infection.
How It’s Identified in the Lab
When doctors suspect Moraxella catarrhalis, a sample from the infected site (such as sputum or middle ear fluid) is sent for culture. The bacterium grows on standard culture plates and tests positive for oxidase, an enzyme it shares with the closely related Neisseria species. To tell them apart, labs use a simple test involving tributyrin or similar compounds. Moraxella catarrhalis breaks down these substances and produces a positive reaction, while all Neisseria species test negative. This quick differentiation is important because the two groups look similar under the microscope but require different treatment approaches.
Vaccine Development
No vaccine currently exists for Moraxella catarrhalis. Researchers have developed an experimental vaccine targeting both this bacterium and nontypeable Haemophilus influenzae, primarily aimed at reducing COPD exacerbations. However, a systematic review of randomized controlled trials found that the vaccine did not significantly reduce exacerbation rates, hospitalizations, or mortality in COPD patients, though it was well tolerated. The challenge of developing an effective vaccine reflects the bacterium’s ability to vary its surface proteins and its complex interactions with the immune system.